Drug Repurposing Strategy

Martin describes how he built value by acquiring abandoned pharmaceutical assets and repurposing them for different diseases, specifically highlighting his first major success.

Key Strategy:

• Find undervalued pharmaceutical assets that big companies abandoned
• Research alternative disease applications through extensive study of medical literature (PubMed)
• Acquire rights to promising drugs for relatively low cost ($2M in example)
• Redirect development toward new disease targets with better market potential

Example Case:

• Acquired drug from Bristol Myers for $2M
• Original purpose: Hypertension (overcrowded market with 60+ existing drugs)
• New application: Rare kidney disease (FSGS)
• Outcome:
  • Drug received FDA approval
  • Company value grew to ~$1.5B
  • First asset became successful after 10 years of development

Key Success Factors:

• Deep research capabilities using PubMed (36M medical papers)
• Understanding both finance/Wall Street expectations and pharmaceutical development
• Ability to identify alternative disease applications that big pharma missed
• Patience for long development cycles (10+ years)
• Focus on rare diseases with unmet medical needs versus crowded markets

Business Model Benefits:

• Low initial capital requirements ($2M for first asset)
• Massive potential upside (turned into $1.5B company)
• Reduced risk by using previously tested drugs
• Clear path to value creation through FDA approval process